000			05545nam a2200421 i 4500
999			_c361215 _d361215
001			361215
003			ES-MaUEC
005			20230102121331.0
006			a||||fo|||| 00| 0
007			cr nn nnnaamaa
008			210331s2021 sz | o |||| 0|eng d
020			_a9783030630461
024	7		_a10.1007/978-3-030-63046-1 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRC771 _b2021 EB
245	0	0	_aLung Inflammation in Health and Disease, Volume I _cedited by Yong-Xiao Wang
250			_aFirst edition 2021
264		1	_aCham _bSpringer International Publishing _c2021
300			_a1 recurso en línea (XV, 409 páginas) _b54 ilustraciones, 38 ilustraciones a color
336			_2rdacontent _aTexto _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_aArchivo de texto _bPDF
490	0		_aAdvances in Experimental Medicine and Biology _x2214-8019 _v1303
490	0		_aBiomedical and Life Sciences (SpringerNature-11642)
490	0		_aBiomedical and Life Sciences (R0) (SpringerNature-43708)
505	0		_a1. Potential role of mast cells in regulating corticosteroid insensitivity in severe asthma -- 2. Galectin-3 Promotes ROS, Inflammation and Vascular Fibrosis in Pulmonary Arterial Hypertension -- 3. Anti-Inflammatory Effects of Statins in Lung Vascular Pathology: From Basic Science to Clinical Trials -- 4. Evolving Schema for Employing Network Biology Approaches to Understand Pulmonary Hypertension -- 5. Pulmonary Inflammation and KRAS Mutation in Lung Cancer -- 6. microRNA Targets for Asthma Therapy -- 7. Roles of genetic predisposition in the sex-bias of pulmonary pathophysiology, as a function of estrogens -- 8. Hypercapnic respiratory failure-driven skeletal muscle dysfunction: It is time for animal mod-els-based mechanistic research -- 9. Role of airway smooth muscle in inflammation related to asthma and COPD -- 10. Systemic Sclerosis and Pulmonary Disease -- 11. Innate Lymphoid Cells in airway inflammation -- 12. Sjogren's Syndrome and pulmonary disease -- 13. Redox Regulation, Oxidative Stress and Inflammation in Group 3 Pulmonary Hypertension -- 14. Sex-Steroid Signaling in Lung Diseases and Inflammation -- 15. Cytokines, Chemokines and Inflammation in Pulmonary Arterial Hypertension -- 16. Interactive roles of CaMKII/Ryanodine Receptor Signaling and Inflammation in Lung Diseases -- 17. Reciprocal Correlations of Inflammatory and Calcium Signaling in Asthma Pathogenesis -- 18. Crosstalk between Lung and Extrapulmonary Organs in Infection and Inflammation -- 19. Inflammation in Pulmonary Arterial Hypertension -- 20. Lysophospholids in Lung Inflammatory Diseases.
520	3		_aRespiratory diseases are leading causes of death and disability globally, with about 65 million people suffering from COPD, and 334 million from asthma, the most common chronic disease. Each year, tens of millions of people develop and can die from respiratory infections such as pneumonia and TB. Systemic inflammation may induce and exacerbate local inflammatory diseases in the lungs, and local inflammation can in turn cause systemic inflammation. There is increasing evidence of the coexistence of systemic and local inflammation in patients suffering from asthma, COPD, and other lung diseases, and the co-morbidity of two or more local inflammatory diseases often occurs. For example, rheumatoid arthritis frequently occurs together with, and promotes the development of, pulmonary hypertension. This co-morbidity significantly impacts quality of life, and can result in death for those affected. Current treatment options for lung diseases are neither always effective, nor often condition-specific; there is a desperate need for novel therapeutics in the field. Additionally, the molecular and physiological significance of most major lung diseases are not well understood, which further impedes development of new treatments, especially in the case of coexistent lung diseases with other inflammatory diseases. Great progress has been made in recent years in many areas of the field, particularly in understanding the molecular geneses, regulatory mechanisms, signalling pathways, and cellular processes within lung diseases, as well as basic and clinical technology, drug discovery, diagnoses, treatment options, and predictive prognoses. This is the first text to aggregate these developments. In two comprehensive volumes, experts from all over the world present state-of-the-art advances in the study of lung inflammation in health and disease. Contributing authors cover well-known as well as emerging topics in basic, translational, and clinical research, with the aim of providing researchers, clinicians, professionals, fellows, and students with new perspectives and concepts. The editor hopes this book will also help to direct future research in lung disease and other inflammatory diseases, and result in the development of novel therapeutics.
988			_aSpringer_BiomedLife_2021
650		7	_2embne _9144209 _aNeumonía
700	1		_aWang, Yong-Xiao. _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
776	0	8	_iPrinted edition: _z9783030630454
776	0	8	_iPrinted edition: _z9783030630478
776	0	8	_iPrinted edition: _z9783030630485
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-63046-1 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b01/2022 _dz _eb _zSI